tiprankstipranks
Pharma Mar SA (PHMMF)
OTHER OTC:PHMMF

Pharma Mar SA (PHMMF) Stock Price & Analysis

41 Followers

PHMMF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$25.88 - $50.52
Previous Close$28.29
Volume166.00
Average Volume (3M)459.00
Market Cap
$527.28M
Enterprise Value$378.87M
Total Cash (Recent Filing)€182.42M
Total Debt (Recent Filing)€42.63M
Price to Earnings (P/E)390.8
Beta0.66
Apr 25, 2024
Dividend Yield2%
Share Statistics
EPS (TTM)0.06
Shares Outstanding17,971,614
10 Day Avg. Volume20
30 Day Avg. Volume459
Standard Deviation1.42
R-Squared0.01
Alpha0.17
Financial Highlights & Ratios
Price to Book (P/B)3.28
Price to Sales (P/S)3.40
Price to Cash Flow (P/CF)18.80
P/FCF Ratio-41.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

PHMMF FAQ

What was Pharma Mar SA’s price range in the past 12 months?
Pharma Mar SA lowest stock price was $25.88 and its highest was $50.52 in the past 12 months.
    What is Pharma Mar SA’s market cap?
    Currently, no data Available
    When is Pharma Mar SA’s upcoming earnings report date?
    Pharma Mar SA’s upcoming earnings report date is Apr 25, 2024 which is 7 days ago.
      How were Pharma Mar SA’s earnings last quarter?
      Pharma Mar SA released its earnings results on Feb 28, 2024. The company reported -$0.403 earnings per share for the quarter, missing the consensus estimate of $0.085 by -$0.488.
        Is Pharma Mar SA overvalued?
        According to Wall Street analysts Pharma Mar SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Pharma Mar SA pay dividends?
          Pharma Mar SA pays a Annually dividend of $0.56 which represents an annual dividend yield of 2%. See more information on Pharma Mar SA dividends here
            What is Pharma Mar SA’s EPS estimate?
            Pharma Mar SA’s EPS estimate is -$0.07.
              How many shares outstanding does Pharma Mar SA have?
              Pharma Mar SA has 18,554,108 shares outstanding.
                What happened to Pharma Mar SA’s price movement after its last earnings report?
                Pharma Mar SA reported an EPS of -$0.403 in its last earnings report, missing expectations of $0.085. Following the earnings report the stock price went down -3.136%.
                  Which hedge fund is a major shareholder of Pharma Mar SA?
                  Currently, no hedge funds are holding shares in PHMMF
                  ---

                  Pharma Mar SA Stock Smart Score

                  N/A
                  Not Ranked
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -42.00%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  0.58%
                  Trailing 12-Months
                  Asset Growth
                  -10.30%
                  Trailing 12-Months

                  Company Description

                  Pharma Mar SA

                  Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
                  ---

                  PHMMF Earnings Call

                  Q4 2024
                  0:00 / 0:00
                  ---

                  PHMMF Stock 12 Months Forecast

                  Average Price Target

                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"38":"$38","77":"$77","-1":"-$1","18.5":"$18.5","57.5":"$57.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,18.5,38,57.5,77],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2022","6":"Nov<br/>2022","9":"Feb<br/>2023","12":"Apr<br/>2023","25":"Apr<br/>2024"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.3,42.738461538461536,39.176923076923075,35.61538461538461,32.05384615384615,28.49230769230769,24.93076923076923,21.369230769230768,17.807692307692307,14.246153846153845,10.684615384615384,7.123076923076923,3.5615384615384613,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.3,42.738461538461536,39.176923076923075,35.61538461538461,32.05384615384615,28.49230769230769,24.93076923076923,21.369230769230768,17.807692307692307,14.246153846153845,10.684615384615384,7.123076923076923,3.5615384615384613,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.3,42.738461538461536,39.176923076923075,35.61538461538461,32.05384615384615,28.49230769230769,24.93076923076923,21.369230769230768,17.807692307692307,14.246153846153845,10.684615384615384,7.123076923076923,3.5615384615384613,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":76.18,"date":1651363200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":74.3,"date":1654041600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":71.29,"date":1656633600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":59.89,"date":1659312000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":56.63,"date":1661990400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":52.62,"date":1664582400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":61.68,"date":1667260800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":72.8,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":68.82,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":66.98,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":57.94,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":47.95,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":46.3,"date":1681430400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Bristol-Myers Squibb
                  Merck & Company
                  Karyopharm Therapeutics
                  AstraZeneca

                  Best Analysts Covering PHMMF

                  1 Year
                  Juan Ros PadillaOddo BHF
                  Not Ranked
                  1 Year Success Rate
                  0/0 ratings generated profit
                  0%
                  1 Year Average Return
                  0.00%
                  upgraded a buy rating a year ago
                  Copying Juan Ros Padilla's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of 0.00% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis